CD28‐mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
JJ316 and JJ319 are rat CD28‐specific monoclonal antibodies (mAb) of the γ1χ isotype with identical co‐stimulatory potency. At a concentration 100–1000‐fold higher than that required for co‐stimulation, JJ316, but not JJ319 induces massive proliferation of all T cell subsets in vitro without T cell receptor (TCR) triggering. “Direct” stimulation by JJ316 is fully blocked by JJ319, indicating that it is not due to cross‐reactivity of JJ316 with the TCR complex or other activating receptors. JJ316 binds much more slowly to primary T cells than JJ319, whereas both antibodies bind with similar kinetics to CD28‐transfected L‐929 cells, suggesting that JJ316 binding to T cells requires redistribution or a conformational change of CD28. In vivo, JJ316 but not JJ319 induces rapid and transient proliferation of most CD4 T cells and, indirectly, of B cells. These data show that TCR engagement is not an absolute prerequisite either in vitro or in vivo for the induction of T cell proliferation through CD28 and suggest that mAb JJ316 is able to stimulate resting T cells directly by recruiting CD28 molecules from an inactive to an active form.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TGN1412 was called a 'superagonist' because it could activate T-cells without the need for prior engagement of the T-cell receptor complex (Tacke et al., 1997;Lühder et al., 2003).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Tacke et al., 1997
In the citing paper
“Unexpectedly, we found that some rat CD28-specific mAbs activated T cells without the need to also engage the TCR [1].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [1]
Citations
Cites
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1
Dustin, M. L., & Springer, T. A. (1989) · Nature · doi:10.1038/341619a0 · Cited by 1,538
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.721 · Cited by 1,127
Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90047-0 · Cited by 1,038
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 909
Cited by
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017
“In addition to ‘classical’ anti-CD28 antibodies, Tacke and Huenig described a ‘superagonistic’ anti-CD28 antibody, able to stimulate T cells without concomitant TCR engagement (Tacke et al., 1997).”
BackgroundLaboratory mice born to wild mice have natural microbiota and model human immune responses
Rosshart, S. P., Herz, J., Vassallo, B. G., Hunter, A., Wall, M. K., Badger, J. H., McCulloch, J. A., Anastasakis, D. G., Sarshad, A. A., Leonardi, I., et al. (2019) · Science · doi:10.1126/science.aaw4361 · Cited by 572
The kinetic-segregation model: TCR triggering and beyond
Davis, S. J., & van der Merwe, P. A. (2006) · Nature Immunology · doi:10.1038/ni1369 · Cited by 561
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
Hofmann, U., & Frantz, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.304072 · Cited by 296
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
“The ability of certain “superagonistic” anti-CD28 antibodies to independently activate T cells suggests that in some circumstances CD28 can function in the absence of a TCR derived signal (Tacke et al. 1997; Luhder et al. 2003).”
BackgroundThe nature of molecular recognition by T cells
Davis, S. J., Ikemizu, S., Evans, E. J., Fugger, L., Bakker, T. R., & van der Merwe, P. A. (2003) · Nature Immunology · doi:10.1038/ni0303-217 · Cited by 226
Xystrakis, E., Dejean, A. S., Bernard, I., Druet, P., Liblau, R., Gonzalez-Dunia, D., & Saoudi, A. (2004) · Blood · doi:10.1182/blood-2004-03-1214 · Cited by 206
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
“The observed differences also may be due to better Fc receptor– mediated cross-linking of the antibody by splenic APCs, which was shown to be essential for superagonistic CD28 stimulation to function (11).”
BackgroundMethodResultSelf-citationThe storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Self-citationLühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021024 · Cited by 193
Self-citationChallenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Lin, C., & Hünig, T. (2003) · European Journal of Immunology · doi:10.1002/eji.200323570 · Cited by 184
Self-citationExperimental Models to Study Development and Function of the Human Immune System In Vivo
Legrand, N., Weijer, K., & Spits, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2053 · Cited by 177
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Self-citationImmune Checkpoints as Therapeutic Targets in Autoimmunity
Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J., & Davis, S. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02306 · Cited by 140
CD28 Signaling via VAV/SLP-76 Adaptors
Raab, M., Pfister, S. M., & Rudd, C. E. (2001) · Immunity · doi:10.1016/s1074-7613(01)00248-5 · Cited by 127
Kalia, V., Penny, L. A., Yuzefpolskiy, Y., Baumann, F. M., & Sarkar, S. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.023 · Cited by 126
Cofilin: a redox sensitive mediator of actin dynamics during T‐cell activation and migration
Samstag, Y., John, I., & Wabnitz, G. H. (2013) · Immunological Reviews · doi:10.1111/imr.12115 · Cited by 107
Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals
Bussiere, J. L., Martin, P. L., Horner, M. J., Couch, J. A., Flaherty, M. M., Andrews, L., Beyer, J. C., & Horvath, C. J. (2009) · International Journal of Toxicology · doi:10.1177/1091581809337262 · Cited by 102
Beyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042564 · Cited by 98
Self-citationTabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Self-citationCD28 co-stimulation: novel insights and applications in cancer immunotherapy
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 92
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
Vijayakumar, G., McCroskery, S., & Palese, P. (2019) · Journal of Virology · doi:10.1128/jvi.01677-19 · Cited by 85
Legrand, N., Cupedo, T., van Lent, A. U., Ebeli, M. J., Weijer, K., Hanke, T., & Spits, H. (2006) · Blood · doi:10.1182/blood-2006-01-0190 · Cited by 82
Self-citationTischner, D. (2006) · Brain · doi:10.1093/brain/awl213 · Cited by 82
Self-citationSignaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“By definition, CD28 superagonists induce polyclonal T cell activation in vitro without the need of concomitant stimulation of the TCR/CD3 complex [5,7].”
BackgroundHaspot, F., Séveno, C., Dugast, A., Coulon, F., Renaudin, K., Usal, C., Hill, M., Anegón, I., Heslan, M., Josien, R., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01018.x · Cited by 79
Skartsis, N., Peng, Y., Ferreira, L. M. R., Nguyen, V. Q., Ronin, É., Müller, Y. D., Vincenti, F. G., & Tang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783282 · Cited by 76
Findlay, L., Eastwood, D., Stebbings, R., Sharp, G., Mistry, Y., Ball, C., Hood, J., Thorpe, R., & Poole, S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.10.013 · Cited by 74
“The term “superagonist” reflects the capability of the antibody to stimulate T cell responseswithout the requirement for engagementof theT cell receptor complex, unlike conventional anti-CD28 antibodies (Luhder et al., 2003; Tacke et al., 1997).”
BackgroundNogai, A., Siffrin, V., Bonhagen, K., Pfueller, C. F., Hohnstein, T., Volkmer-Engert, R., Brück, W., Stadelmann, C., & Kamradt, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.959 · Cited by 74
After TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“signals required for T-cell activation (Jenkins et al., 1991; Tacke et al., 1997; Lühder et al., 2003).”
BackgroundSafety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Beyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.06.001 · Cited by 66
Self-citationTreatment of multiple sclerosis: recent trials and future perspectives
Noseworthy, J. H., Gold, R., & Hartung, H. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199906000-00007 · Cited by 66
Adaptive Immune Responses Contribute to Post-ischemic Cardiac Remodeling
Santos‐Zas, I., Lemarie, J., Tedgui, A., & Ait‐Oufella, H. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00198 · Cited by 64
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
CD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63
Self-citationWong, K., Briddon, S. J., Holliday, N. D., & Kerr, I. D. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.002 · Cited by 62
Williams, J. A., Hathcock, K. S., Klug, D. B., Harada, Y., Choudhury, B., Allison, J. P., Abe, R., & Hodes, R. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4199 · Cited by 62
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 61
Xystrakis, E., Cavaillès, P., Dejean, A. S., Cautain, B., Colacios, C., Lagrange, D., Mj, V. D. G., Bernard, I., Gonzalez‐Dunia, D., Damoiseaux, J. G. M. C., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3140 · Cited by 60
Schmidt, J., Elflein, K., Stienekemeier, M., Rodriguez-Palmero, M., Schneider, C., Toyka, K. V., Gold, R., & Hünig, T. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00182-6 · Cited by 59
“injections of 1 mg of the monoclonal antibodies JJ316 (Tacke et al., 1997) or JJ319 (Tacke et al.”
BackgroundInfluentialSelf-citationBode, U., Wonigeit, K., Pabst, R., & Westermann, J. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270837 · Cited by 58
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
Self-citationSoto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
Immunotherapy in autoimmune neuromuscular disorders
Gold, R., Dalakas, M. C., & Toyka, K. V. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00264-3 · Cited by 55
A more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats
Laskowski, I. A., Pratschke, J., Wilhelm, M. J., Dong, V. M., Beato, F., Taal, M. W., Gasser, M., Hancock, W. W., Sayegh, M. H., & Tilney, N. L. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132519 · Cited by 54
Subra, J., Cautain, B., Xystrakis, E., Mas, M., Lagrange, D., van der Heijden, H., Mj, V. D. G., Druet, P., Fournié, G. J., Saoudi, A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.2944 · Cited by 53
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models
Mäurer, M., Toyka, K. V., & Gold, R. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(01)00302-9 · Cited by 50
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S.-W. (2021) · Vaccines · doi:10.3390/vaccines9070724 · Cited by 48
OX40R (TNFRSF4) bound to Fab 1A7
Yang, Y., Yeh, S. H., Madireddi, S., Matochko, W. L., Gu, C., Sanchez, P. P., Ultsch, M. H., Boenig, G. D. L., Harris, S. F., Leonard, B. C., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1625662 · Cited by 48
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Self-citationA CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses
Dennehy, K. M., Elias, F., Zeder-Lutz, G., Ding, X., Altschuh, D., Lühder, F., & Hünig, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5725 · Cited by 46
Self-citationIndependent CD28 signaling via VAV and SLP‐76: a model for in trans costimulation
Rudd, C. E., & Raab, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00005.x · Cited by 46
Dennehy, K. M., Elias, F., Na, S.-Y., Fischer, K.-D., Hünig, T., & Lühder, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1363 · Cited by 45
“Lastly, induction of NF- B and Bcl-XL by superagonistic but not conventional CD28 Abs (13, 18, 19, 64) suggests that these events also result from CD28 and TCR signal integration, in direct contrast to recent reports (5, 7).”
BackgroundInfluentialSelf-citationTGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals
Bhogal, N., & Combes, R. (2006) · Alternatives to Laboratory Animals · doi:10.1177/026119290603400204 · Cited by 45
Superagonism at G protein‐coupled receptors and beyond
Schrage, R., Min, A. D., Hochheiser, K., Kostenis, E., & Mohr, K. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13278 · Cited by 45
The intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 46
Lymphocytic subsets play distinct roles in heart diseases
Wang, J., Duan, Y., Sluijter, J. P. G., & Xiao, J. (2019) · Theranostics · doi:10.7150/thno.33112 · Cited by 42
Kerstan, A., & Hünig, T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1341 · Cited by 41
Self-citationKitazawa, Y., Fujino, M., Li, X.-K., Xie, L., Ichimaru, N., Okumi, M., Nonomura, N., Tsujimura, A., Isaka, Y., Kimura, H., et al. (2009) · Cell Transplantation · doi:10.1177/096368970901805-619 · Cited by 41
Self-citationStorm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
Horvath, C. J., Andrews, L., Baumann, A., Black, L. E., Blanset, D. L., Cavagnaro, J. A., Hastings, K. L., Hutto, D., MacLachlan, T. K., Milton, M., et al. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c1 · Cited by 41
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 40
Otz, T., Große-Hovest, L., Hofmann, M., Rammensee, H.-G., & Jung, G. (2009) · Leukemia · doi:10.1038/leu.2008.271 · Cited by 38
Supra‐physiological efficacy at GPCRs : superstition or super agonists?
Langmead, C. J., & Christopoulos, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12142 · Cited by 38
Przybył, Ł., Ibrahim, T., Haase, N., Golić, M., Rugor, J., Luft, F. C., Bendix, I., Serdar, M., Wallukat, G., Staff, A. C., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04892 · Cited by 38
Self-citationEffector pathways regulating T cell activation
Favero, J. J., & Lafont, V. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00213-5 · Cited by 38
Siefken, R., Klein-Heßling, S., Serfling, E., Kurrle, R., & Schwinzer, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1645 · Cited by 37
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 38
Dong, V. M., Yuan, X., Coito, A. J., Waaga, A. M., Sayegh, M. H., & Chandraker, A. K. (2002) · Transplantation · doi:10.1097/00007890-200204270-00021 · Cited by 37
Perspectives on PKC? in T cell activation
Sedwick, C. E., & Altman, A. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.01.007 · Cited by 37
Dennehy, K. M. (2003) · International Immunology · doi:10.1093/intimm/dxg063 · Cited by 36
Lippert, A. H., Paluch, C., Gaglioni, M., Vuong, M. T., McColl, J. T., Jenkins, E. M., Fellermeyer, M., Clarke, J., Sharma, S., da Silva, S. M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.007 · Cited by 36
Guillonneau, C., Séveno, C., Dugast, A., Li, X., Renaudin, K., Haspot, F., Usal, C., Véziers, J., Anegón, I., & Vanhove, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.12.8164 · Cited by 35
Beyersdorf, N., Ding, X., Blank, G., Dennehy, K. M., Kerkau, T., & Hünig, T. (2008) · Blood · doi:10.1182/blood-2008-03-146662 · Cited by 32
Self-citationvan den Brandt, J., Wang, D., & Reichardt, H. M. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0390 · Cited by 31
CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation
Hünig, T., Lühder, F., Elflein, K., Gogishvili, T., Fröhlich, M., Guler, R., Cutler, A. J., & Brombacher, F. (2010) · Medical Microbiology and Immunology · doi:10.1007/s00430-010-0156-z · Cited by 30
Self-citationParalysis of CD4+CD25+ regulatory T cell response in chronic autoimmune encephalomyelitis
Matsumoto, Y., Sakuma, H., Kohyama, K., & Park, I.-K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.04.004 · Cited by 29
CD28, Costimulator or Agonist Receptor?
Margulies, D. H. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030303 · Cited by 29
Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
Superagonistic CD28 Antibody Induces Donor-Specific Tolerance in Rat Renal Allografts
Azuma, H., Isaka, Y., Li, X., Hünig, T., Sakamoto, T., Nohmi, H., Takabatake, Y., Mizui, M., Kitazawa, Y., Ichimaru, N., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02358.x · Cited by 28
Self-citationHoen, E. N. M. N., Wagenaar-Hilbers, J. P. A., Boot, E. P. J., Lin, C., Arkesteijn, G. J. A., van Eden, W., Taams, L. S., & Wauben, M. H. M. (2004) · European Journal of Immunology · doi:10.1002/eji.200324725 · Cited by 28
Kitazawa, Y., Fujino, M., Sakai, T., Azuma, H., Kimura, H., Isaka, Y., Takahara, S., Hünig, T., Abe, R., & Li, X. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.004 · Cited by 28
Self-citationTCRαβ-Independent CD28 Signaling and Costimulation Require Non-CD4-Associated Lck
Leung, B., Haughn, L., Veillette, A., Hawley, R. G., Rottapel, R. K., & Julius, M. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1334 · Cited by 28
Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire
Olive, D., le Thi, S., Xerri, L., Hirsch, I., & Nunès, J. A. (2011) · médecine/sciences · doi:10.1051/medsci/20112710012 · Cited by 27
Rapid recovery from T lymphopenia by CD28 superagonist therapy
Elflein, K., Rodriguez-Palmero, M., Kerkau, T., & Hünig, T. (2003) · Blood · doi:10.1182/blood-2002-11-3586 · Cited by 25
Self-citation1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept
Gardner, D. H., Jeffery, L. E., Soskic, B., Briggs, Z., Hou, T. Z., Raza, K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500306 · Cited by 25
Costimulation and Autoimmune Diabetes in BB Rats
Beaudette-Zlatanova, B. C., Whalen, B. J., Zipris, D., Yagita∥, H., Rozing, J., Groen, H., Benjamin, C. D., Hünig, T., Drexhage, H. A., Ansari, M. J., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01227.x · Cited by 25
Self-citationCautain, B., Damoiseaux, J. G. M. C., Bernard, I., Xystrakis, E., Fournié, E. L., Vriesman, P. J. C. V. B., Druet, P., & Saoudi, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.162 · Cited by 25
The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes
Schnaider, T., Somogyi, J., Csermely, P., & Szamel, M. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00352-x · Cited by 25
Serra, A., Nuti, S., Tavarini, S., Sammicheli, C., Rosa, D., Saletti, G., Soldaini, E., Abrignani, S., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.174 · Cited by 24
Metadata
- Authors
- Tacke, M., Hanke, G., Hanke, T., & Hünig, T.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1997-01
- Volume
- 27
- Issue
- 1
- Pages
- 239-247
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1986805605
- Cited by
- 163
- References
- 39
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 9 · 2018: 6 · 2017: 4 · 2016: 2 · 2015: 8 · 2014: 5 · 2013: 8 · 2012: 6
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD28, T cell costimulation, T cell proliferation, resting T cells, T cell receptor, monoclonal antibodies, CD4+ T cells, B cell activation, T cell activation
- MeSH terms
- Animals, Antibodies, Monoclonal, Cell Division, Female, Kinetics, Lymph Nodes, Lymphocyte Activation, Male, Membrane Glycoproteins, Rats, Inbred Lew, Receptors, Antigen, T-Cell, Spleen, T-Lymphocytes, Signal Transduction, Antigens, CD, Lymphocyte Subsets, CD28 Antigens, B7-1 Antigen, Rats, B7-2 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.